XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting Peptide Therapy of Chronic Heart Failure using PASylation® Technology Kumar Jeetendra | October 22, 2020 SAN DIEGO, U.S.A., and FREISING, Germany, October 15, 2020 – Life Science Newswire – Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a strategic slliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to …
